Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma

drugsJune 12, 2019

Tag: FDA , Keytruda , pembrolizumab , neck , squamous

PharmaSources Customer Service